



Garvan Institute of Medical Research

Leaders in Science & Society



Prof Matt Cooper

Institute for Molecular Bioscience
The University of Queensland

“Infection and innate immunity: Follow the bugs to get to the drugs”

Monday 10 April 2017 12PM, AUDITORIUM

Host: Prof Stuart Tangye

Prof. Matt Cooper completed his PhD in 1995 and then spent 13 years in the UK, first at the University of Cambridge, then 9 years in start-ups and biotechnology companies. He returned to Australia in 2009 as a NHMRC Australia Fellow, at the University of Queensland, where he is driving research and development of infectious and inflammatory disease diagnostics and therapeutics. He was founder and Managing Director of Cambridge Medical Innovations (part of Alere Inc.) and CSO and co-founder of Akubio, and co-founder of Defensin Therapeutics. He has more than 225 scientific articles, 2 books, 5 book chapters, 27 patents, and has helped launch multiple medical technology products on the market today. Professor Matthew Cooper is CEO and a shareholder in Inflazome Ltd. This company is developing drugs to address clinical unmet needs in inflammatory disease by targeting inflammasomes. Professor Cooper also holds a Professorial Research Fellow appointment at the University of Queensland.